Search

Displaying results 4231 - 4240 of 9889 in total
  1. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due

  2. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and

  3. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated

    Synonyms: Hu-rhEGF-rP64k/Mont
  4. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

  5. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … [A262056] Repotrectinib possesses a compact macrocyclic structure that both limits adverse interactions with resistance mutation hotspots and targets mutations in the solvent-front region.

    Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE
  6. Drug

    Protriptyline

    go.drugbank.com/drugs/DB00344
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.

    Synonyms: 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene, 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
  7. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … Salsalate is a nonsteroidal anti-inflammatory agent for oral administration.

  8. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.

  10. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.